Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer

Current guidelines for lung cancer treatment with EGFR tyrosine kinase inhibitors (TKI) include only patients with mutated EGFR, although some patients with wildtype EGFR (wt-EGFR) have exhibited positive responses to this therapy as well. Biomarkers predicting the benefit from EGFR-TKIs treatment r...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Naiqing, Fang, Wenfeng, Mu, Libing, Tang, Yanna, Gao, Lei, Ren, Shengxiang, Cao, Dengfeng, Zhou, Lixin, Zhang, Aiqun, Liu, Deruo, Zhou, Caicun, Wong, Kwok-Kin, Yu, Lei, Zhang, Li, Chen, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826177/
https://www.ncbi.nlm.nih.gov/pubmed/26646697
http://dx.doi.org/10.18632/oncotarget.6461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826177/
https://www.ncbi.nlm.nih.gov/pubmed/26646697
http://dx.doi.org/10.18632/oncotarget.6461

Ejemplares similares